



Press release

## **Global Life Science Ventures makes further investment into Xantos Biomedicine AG**

**Munich/Zug/London**, 13 September 2004 – *Global Life Science Ventures (GLSV)* today announced that it has made a further investment into Xantos Biomedicine AG. The third round financing, which raised a total of €4 million for the company, comprised the existing syndicate of GLS I, Alta Partners, GIMV, Oxford Bioscience Partners (OBP) and GLSV II. Xantos Biomedicine, which is located in Munich, Germany, uses proprietary advanced robotic methods and functional genomic approaches to assist in the development of new drugs and diagnostics for cancer and metabolic diseases.

Dr. Peter Reinisch, Partner of Global Life Science Ventures, commented: "Xantos Biomedicine AG has made significant progress since its last financing round in 2001. It not only came up with unique discoveries in cancer and metabolic diseases, but also started generating first revenues by offering development solutions to leading pharmaceutical and biotech partners." He added: "The company will also generate further income from significant grants." Hanns-Peter Wiese, Partner of Global Life Science Ventures, remarked: "These achievements formed the basis for the successful closing of this new financing round in a difficult economic environment. They were also made possible by the assistance of the silent partners tbg and Bayern Kapital and give Xantos the chance to reach its next ambitious goals."

Stephan Wehselau, Chief Executive Officer of Xantos, remarked: "Our company continues to make good progress as we continue to implement our business strategy on several fronts. We are extremely pleased by the confidence international investors like Global Life Science Ventures are showing in the further development of our company." He added: "The combined ongoing support of all our investors will deliver direct benefits to Xantos as we pursue our collaborations with pharma and biotech partners. It also enables us to explore new opportunities in our service business and develop further our internal target identification and drug discovery projects."

### **About Global Life Science Ventures:**

GLSV is a leading, independent venture capital fund focusing exclusively on the life sciences. With offices in Germany, Switzerland, and the UK, GLSV is dedicated to providing finance primarily to early-stage groups, originating from universities, scientific institutions or industry, as well as selected later stage companies, including buy-outs. The group currently advises and manages funds greater than €200 million. Up to now, GLSV has financed 29 leading biotechnology companies, five of which have completed a successful exit through IPO or trade-sale. GLSV has built a broadly diversified portfolio of companies in pharmaceuticals, diagnostics, medical devices, and biotechnology.



**Global Life Science Ventures – one team – three locations – global perspective**

**Germany**

GLSV GmbH  
Von-der-Tann-Str. 3  
D – 80539 München  
Tel. +49 (0)89 288 151 0  
Fax +49 (0)89 288 151 30  
[www.glsv-vc.com](http://www.glsv-vc.com)  
[mailbox@glsv-vc.com](mailto:mailbox@glsv-vc.com)

**Switzerland**

GLSV AG  
Postplatz 1, P.O. 626  
CH – 6301 Zug  
Tel. +41 (0)41 727 19 40  
Fax +41 (0)41 727 19 45

**UK**

GLSV Ltd.  
1, Northumberland Avenue  
London WC2N 5BW, UK  
Tel. +44 (0)20 89 38 66 92  
Fax +44 (0)20 89 38 77 40

For additional information, please contact:

**Rochat & Partners**

Christophe Lamps  
Tel. +41 22 718 37 46  
Fax +41 22 786 54 58  
E-mail: [clamps@rochat-pr.ch](mailto:clamps@rochat-pr.ch)